Expert opinion on drug discovery · 2026
A network-driven antiviral discovery pipeline for emerging RNA viruses: a critical perspective from the Red Mexicana de Desarrollo de Antivirales (RMDA).
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
De Jesús-González Luis Adrián, Santos-Mena Alan Orlando, Farfán-Morales Carlos Noé, León-Juárez Moisés, Reyes-Ruiz José Manuel, Osuna-Ramos Juan Fidel, Cordero-Rivera Carlos Daniel, Palacios-Rápalo Selvin Noé, Lira-Hernández Flor Itzel, Del Ángel Rosa María
Аннотация
INTRODUCTION: RNA viruses impose a disproportionate burden of emerging and reemerging infectious diseases in Latin America, yet antiviral discovery in the region remains fragmented, target-limited, and frequently disconnected from translational pathways. This perspective discusses the Red Mexicana de Desarrollo de Antivirales (RMDA) as a network-driven model to organize antiviral discovery against clinically relevant RNA viruses.
AREAS COVERED: The authors describe the conceptual architecture of RMDA, a multi-institutional Mexican initiative that integrates computational prioritization, cell-based antiviral evaluation under BSL-2/BSL-3 conditions, mechanistic virology, assessment of pharmacological synergy, in vivo validation, and clinical linkage through healthcare systems such as the Instituto Mexicano del Seguro Social. The framework is supported by prior work from participating groups on host-directed and virus-directed candidates, including metabolic modulators, lipid-lowering agents, nuclear transport inhibitors, natural products, polyphenols, melatonin, and rational drug combinations evaluated against dengue virus, Zika virus, SARS-CoV-2, respiratory syncytial virus, and related RNA viruses.
EXPERT OPINION: RMDA provides a scalable and regionally adaptable model for antiviral drug discovery in low- and middle-income settings. By aligning distributed expertise, standardized workflows, and translational decision points, this framework may accelerate candidate prioritization, reduce duplication, and strengthen preparedness against RNA virus threats in Mexico and Latin America.
AREAS COVERED: The authors describe the conceptual architecture of RMDA, a multi-institutional Mexican initiative that integrates computational prioritization, cell-based antiviral evaluation under BSL-2/BSL-3 conditions, mechanistic virology, assessment of pharmacological synergy, in vivo validation, and clinical linkage through healthcare systems such as the Instituto Mexicano del Seguro Social. The framework is supported by prior work from participating groups on host-directed and virus-directed candidates, including metabolic modulators, lipid-lowering agents, nuclear transport inhibitors, natural products, polyphenols, melatonin, and rational drug combinations evaluated against dengue virus, Zika virus, SARS-CoV-2, respiratory syncytial virus, and related RNA viruses.
EXPERT OPINION: RMDA provides a scalable and regionally adaptable model for antiviral drug discovery in low- and middle-income settings. By aligning distributed expertise, standardized workflows, and translational decision points, this framework may accelerate candidate prioritization, reduce duplication, and strengthen preparedness against RNA virus threats in Mexico and Latin America.